Protalix BioTherapeutics, Inc. (PLX)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$2.67+1.91%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PLX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 80.6 | 52.7 | 53.4 | 65.5 | 47.6 | 38.4 | 62.9 | 54.7 | — | 21.1 | 9.2 | 4.4 | 3.5 | 0.0 | 34.9 | 8.4 |
| Total Revenues | 80.6 | 52.7 | 53.4 | 65.5 | 47.6 | 38.4 | 62.9 | 54.7 | — | 21.1 | 9.2 | 4.4 | 3.5 | 0.0 | 34.9 | 8.4 |
| Cost of Revenues | 24.8 | 27.0 | 24.3 | 23.0 | 19.6 | 16.3 | 10.9 | 10.9 | 9.3 | 15.2 | 8.4 | 0.7 | 0.6 | 0.0 | 8.1 | 1.5 |
| Gross Profit | — | — | — | — | — | — | — | — | — | 4.0 | 0.8 | 3.6 | 2.9 | 0.0 | 26.3 | 1.4 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 12.6 | 11.7 | 12.2 | 15.0 | 11.7 | 12.7 | 11.1 | 9.9 | 10.9 | 11.5 | 9.4 | 7.3 | 9.2 | — | — | — |
| R&D Expenses | 19.9 | 19.6 | 13.0 | 17.1 | 29.3 | 29.7 | 38.2 | 44.6 | 33.3 | 32.2 | 30.4 | 24.9 | 27.4 | 29.2 | 36.7 | 37.8 |
| Operating Income | 23.3 | (5.5) | 3.9 | 10.5 | (13.0) | (20.5) | 2.7 | (10.7) | (19.3) | (34.5) | (33.2) | (23.7) | (28.6) | (34.1) | (12.2) | (36.5) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | 3.5 | 3.5 | 1.0 | — | — |
| Other Non-Operating Income / Expenses | 0.2 | (0.1) | 0.2 | (1.9) | (1.4) | (7.1) | (9.2) | (7.6) | (7.1) | (48.9) | 4.0 | (3.6) | (4.7) | (0.7) | — | — |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | — |
| EBT, Incl. Unusual Items | 23.5 | (5.6) | 4.2 | 8.6 | (14.4) | (27.6) | (6.5) | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | 4.5 | 1.0 | 1.2 | 0.3 | 0.5 | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | 18.9 | (6.6) | 2.9 | 8.3 | (14.9) | (27.6) | (6.5) | (18.3) | (26.5) | (83.4) | (29.4) | 58.0 | (29.9) | (27.8) | (11.6) | (36.5) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.24 | (0.08) | 0.04 | 0.12 | (0.31) | (0.62) | (0.22) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | 0.23 | (0.08) | 0.04 | 0.09 | (0.31) | (0.62) | (0.22) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 0.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 80.0 | 78.5 | 72.5 | 67.5 | 48.5 | 44.1 | 29.1 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 82.6 | 78.5 | 81.1 | 82.4 | 48.5 | 44.1 | 29.1 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBIT | 23.3 | (5.5) | 3.9 | 10.5 | (13.0) | (20.5) | 2.7 | (10.7) | (19.3) | (34.5) | (33.2) | (23.7) | (28.6) | (34.1) | (12.2) | (36.5) |
| Effective Tax Rate | 19.3% | — | — | 3.0% | -3.7% | — | — | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.